Опубликована: Дек. 24, 2024
In the rapidly evolving pharmaceutical industry, Lifecycle Management (LCM) strategies are critical for maximizing profitability and extending market life of drugs. This study investigates strategic importance expanding indications sodium-glucose cotransporter 2 (SGLT2) inhibitors before expiration their foundational patents. By analyzing these pre-expiration strategies, balance between genuine innovation evergreening is addressed. The analysis covers legal, regulatory, clinical dimensions indication expansions across US, EU, Japan, contrasting with traditional focus on LCM post-patent expiration.
Язык: Английский